Pritumumab - Nascent Biotech
Alternative Names: ACA 11; CLN-IgG; CLNH 11; Monoclonal antibody ACA 11Latest Information Update: 28 Apr 2024
At a glance
- Originator University of California, San Diego
- Developer Nascent Biotech
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Glioma
- No development reported Brain cancer; COVID 2019 infections; Pancreatic cancer
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Brain-cancer(Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Apr 2024 No recent reports of development identified for research development in COVID-2019-infections in USA (Parenteral)
- 29 Nov 2023 Nascent Biotech receives Notice of Allowance for a Method of Use patent for pritumumab in Japan